Basic research has demonstrated that sensitivity of cancers to inducers of RS is highly dependent on markers, with most clinical development programs recently focusing on a narrower group of populations with such markers as CCNE and MYC amplifications, RB1 and TP53 mutations and others. Here, TP53 is linked to cancer.